10-K: Nordicus Partners Reports Significant Life Sciences Portfolio Growth Amidst Widening Losses and Going Concern Doubts

Nordicus Partners Corporation, a U.S. business accelerator for Nordic life sciences companies, reported substantial expansion of its preclinical biotechnology portfolio through key acquisitions and promising drug development milestones, alongside a significant increase in operating expenses and net losses for the fiscal year ended March 31, 2025.

Summary

• Nordicus Partners Corporation has transformed into a U.S. publicly listed business accelerator and holding company focused on Nordic life sciences.
• Acquired 95% of Orocidin A/S in May 2024 for 3,800,000 restricted common shares, and the remaining 5% in November 2024 for 200,000 restricted common shares, making it a 100% wholly-owned subsidiary.
• Acquired 100% of Bio-Convert A/S in November 2024 for 12,000,000 restricted common shares.
• Orocidin A/S, a preclinical-stage biotechnology company, is developing a medical treatment for aggressive periodontitis (QR-01).
• Bio-Convert A/S, also preclinical, is developing a treatment for oral leukoplakia (QR-02) to reduce the risk of oral cancer.
• Orocidin A/S successfully completed a 14-day toxicology study in hamsters with high drug tolerance and no adverse reactions.
• Orocidin A/S's QR-01 showed consistent improvements across key clinical endpoints (Gingival Index, Plaque Index, overall periodontal disease) in a 13-day Beagle Dog Study, with no adverse side effects.
• Bio-Convert A/S received positive scientific advice from the Danish Medicines Agency (DKMA) for QR-02, potentially allowing a First in Human trial without further animal studies.
• Revenue increased by 100% to $5,000 for the year ended March 31, 2025, from $2,500 in the prior year.
• Total operating expenses surged to $2,924,365 in FY2025 from $310,088 in FY2024, primarily due to increased officer compensation, professional fees, consulting expenses, general and administrative costs, and $1,329,436 in research and development expenses from the newly acquired subsidiaries.
• Net loss widened to $(2,917,280) in FY22025 from $(298,202) in FY2024.
• Cash used in operating activities increased to $1,284,615 in FY2025 from $258,928 in FY2024.
• Total assets significantly increased to $70,246,329 as of March 31, 2025, from $1,807,573 as of March 31, 2024, largely due to the recognition of $42,708,079 in in-process research and development (IPR&D) and $25,490,751 in goodwill from the acquisitions.
• The company's common stock underwent a 1-for-10 reverse stock split on November 8, 2024.
• As of July 16, 2025, there were 17,487,138 shares of common stock outstanding.

Sentiment

Score: 3

Explanation: While the company has made significant strategic acquisitions and its portfolio companies show promising preclinical results, the substantial increase in net losses, operating expenses, and cash burn, coupled with the explicit 'going concern' warning and ineffective internal controls, indicates a highly challenging financial position. The positive developments are early-stage and require significant future funding, which is a major concern given current liquidity.

Positives

• Successful completion of a 14-day toxicology study for Orocidin A/S's QR-01 in hamsters, showing high tolerance and no adverse reactions.
• Positive results from Orocidin A/S's Beagle Dog Study, demonstrating QR-01's direct effect on periodontitis and consistent improvements in key clinical endpoints.
• Bio-Convert A/S received positive scientific advice from the Danish Medicines Agency (DKMA) for QR-02, potentially allowing a First in Human trial without further animal studies.
• Strategic acquisitions of Orocidin A/S and Bio-Convert A/S significantly expand the company's life sciences portfolio with promising preclinical biotechnology assets.
• Revenue increased by 100% year-over-year, from $2,500 to $5,000.
• Total assets grew substantially from $1,807,573 to $70,246,329, reflecting significant investments in IPR&D and goodwill from acquisitions.
• The company relisted on the OTCQB Market on May 9, 2024, enhancing market visibility.

Negatives

• Net loss significantly widened to $(2,917,280) for the year ended March 31, 2025, compared to $(298,202) in the prior year.
• Total operating expenses increased by 843% to $2,924,365, driven by higher officer compensation, professional fees, consulting expenses, general and administrative costs, and new research and development expenses.
• Cash used in operating activities increased to $1,284,615, indicating a higher cash burn rate.
• Cash on hand decreased from $49,933 to $19,914.
• The company has nominal revenue and has incurred losses since inception, resulting in an accumulated deficit of $46,784,848 as of March 31, 2025.
• Management concluded that disclosure controls and procedures and internal control over financial reporting were not effective due to limited resources.

Risks

• Substantial doubt about the ability to continue as a going concern due to nominal revenue and accumulated deficit.
• The company's shares are subject to Section 15(g) and Rule 15g-9 of the Securities and Exchange Act, commonly referred to as the penny stock rule, which may restrict the ability of broker-dealers to trade or maintain a market in common stock and affect shareholders' ability to sell shares.
• The company's ability to use its net operating loss carryforwards may be substantially limited due to ownership change limitations under Section 382 of the Internal Revenue Code.
• Operations are subject to factors that can affect operating results and financial condition, including the results of research and development, clinical testing and trial activities of the company's products.
• The company faces risks related to its ability to obtain regulatory approval to market its products.
• Competition from products manufactured and sold or being developed by other companies poses a risk.
• The price of, and demand for, the company's products can impact its financial performance.
• The company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products is a risk factor.
• The company's ability to raise capital is a critical factor affecting its operations.
• Cybersecurity threats to data, systems, and business operations are a risk, although they have not materially affected the company to date.

Future Outlook

The company aims to take all portfolio companies' drug developments through Phase I clinical trials. Upon completion of Phase I, strategic options include sale or merger of the portfolio company, further development through next clinical phases, strategic partnership with a large pharmaceutical company, or a stand-alone Initial Public Offering (IPO). Management intends to finance operating costs over the next twelve months with existing cash on hand and the private placement of Common Stock.

Management Comments

• Since the current leadership assumed control of Nordicus Partners Corporation, the Company has evolved into a leading U.S. publicly listed business accelerator and holding company dedicated to helping Nordic life sciences companies succeed in the American market.
• By combining Nordic innovation with U.S. operational expertise, Nordicus Partners Corporation creates a distinct advantage in identifying, scaling, and exiting high-potential companies in fast-growing markets with unmet medical needs.
• Nordicus' mission is to back high-growth ventures and transformative innovations in the life sciences sector. By providing capital, strategic guidance, and operational resources, we unlock each company's potential to generate significant value and drive robust financial returns.
• Our hands-on approach—engaging, empowering, and capitalizing our portfolio companies—actively propels their success.
• Nordicus' portfolio diversification strategy positions us as a stable and resilient company, mitigating risk with significant upside potential.
• The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study.
• This represents a significant milestone for Orocidin's lead product, QR-01, and strengthens Nordicus and Orocidin's confidence as Orocidin prepare for the upcoming human pilot efficacy study.
• DKMA's feedback paves the way toward a First in Human trial, with a high likelihood of animal studies rendered dispensable for the proposed formulation and route of application.
• Our current funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these consolidated financial statements.
• Management intends to finance operating costs over the next twelve months with existing cash on hand and the private placement of Common Stock.
• Our disclosure controls and procedures as of March 31, 2025, were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.
• Our internal controls over financial reporting were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Industry Context

Nordicus Partners Corporation is positioning itself as a unique player in the life sciences sector by focusing on accelerating Nordic biotechnology companies into the American market. This strategy leverages the strong innovation pipeline often found in Nordic countries with the vast capital and market opportunities of the U.S. The acquisitions of Orocidin A/S and Bio-Convert A/S demonstrate a clear focus on oral health, a niche but potentially high-growth area with unmet medical needs, particularly for conditions like aggressive periodontitis and oral leukoplakia. The company's approach of taking preclinical assets through Phase I trials before considering various exit strategies aligns with common venture capital and biotech accelerator models, aiming to de-risk assets for larger pharmaceutical partners or public markets. The significant increase in R&D expenses reflects the typical investment required in early-stage drug development within the biotechnology industry.

Management Changes

Corporate Governance

Legal Proceedings

• None. The company is not the subject of any pending legal proceedings, and no proceedings are presently contemplated against it by any federal, state, or local governmental agency. No director or executive officer is party to any action with an adverse interest to the company.

Related Party Transactions

• GK Partners ApS, controlled by the spouse of a former director, received and exercised warrants to purchase common stock, generating proceeds of $576,000 in FY2025 and $313,455 from a new warrant in FY2025.
• Legal fees of $79,463 in FY2025 and $17,022 in FY2024 were paid to a legal counsel affiliated with Bennett Yankowitz, the CFO and a director.
• A related party forgave a payable of $13,886 during FY2025, which was credited to additional paid-in capital.
• Acquisitions of NP Bioinnovation A/S, Orocidin A/S, and Bio-Convert A/S involved individuals who were or are related parties (e.g., Tom Glaesner Larsen, Allan Wehnert, Christian Hill-Madsen) through beneficial ownership or management roles in the acquired entities.
• Henrik Rouf (CEO) and Bennett J. Yankowitz (CFO & Director) received significant salary increases through amended employment/consulting agreements, effective April 8, 2024, and July 1, 2025.

Stakeholder Impact

• Shareholders: Significant dilution from stock-based acquisitions (Orocidin, Bio-Convert) and private placements. Potential for future value creation if preclinical assets succeed, but current substantial losses and going concern warning pose high risk. Subject to penny stock rules which may limit liquidity.
• Employees/Management: Increased compensation for officers and directors, and new stock incentive plan, aiming to attract and retain talent.
• Customers/Partners: Focus on Nordic life sciences companies as 'accelerator clients' and potential strategic partners for drug development.
• Creditors: The 'going concern' warning indicates increased risk for creditors, though the company's liabilities are primarily deferred tax and accounts payable, with recent capital raises.

Next Steps

• Orocidin A/S to conduct an upcoming pivotal 8-week toxicity study for QR-01.
• Orocidin A/S to prepare for an upcoming human pilot efficacy study for QR-01.
• Bio-Convert A/S to proceed toward a First in Human trial for QR-02.
• Nordicus aims to take all portfolio companies' drug developments through Phase I.
• Upon completion of Phase I, consider sale or merger of portfolio company, further development through next clinical phases, strategic partnership with a large pharmaceutical company, or stand-alone Initial Public Offering (IPO).
• Management intends to take appropriate and reasonable steps to make improvements to remediate deficiencies in disclosure controls and internal control over financial reporting if successful in effecting a transaction with an operating company.
• Management intends to finance operating costs over the next twelve months with existing cash on hand and the private placement of Common Stock.

Key Dates

Recommendation

Despite strategic acquisitions of promising preclinical assets in the life sciences sector, the company's financial health is severely distressed. The substantial increase in net losses, operating expenses, and cash burn, coupled with the explicit 'going concern' warning from auditors and management's admission of ineffective internal controls, indicates a high level of operational and financial risk. While the preclinical study results for Orocidin and Bio-Convert are positive, they are very early stage and require significant, uncertain future funding and regulatory approvals. The company's reliance on private placements for short-term liquidity and its penny stock status further underscore its precarious position. The current financial trajectory suggests a high probability of further dilution or financial distress, making it an unfavorable investment at this time.

Keywords

Life Sciences, Biotechnology, Oral Health, Periodontitis, Oral Leukoplakia, Drug Development, Preclinical Stage, Business Accelerator, Holding Company, Nordic Innovation, SEC Filing, 10-K, Biopharma, Medical Devices, Clinical Trials, Pharmaceuticals